Chemagis Ltd.

Sol-gel Technologies Ltd.

Agis Industries (1983) Ltd.

Eve Pharma Ltd.

Stephen Cherkez

Oded Arad

Vladimir Naddaka

Shady Saeed

Venkateswarlu Jasti

Joseph Kaspi

Eran Eilat

Ori Lerman

Veera Reddy Arava

Moshe Arkin

Eyal Klopfer

Madhusudhanarao Rayapureddi

Michael Tennenbaum

Ilana Lavon

Amira Zeevi

Chalil Abu-Gnim

Tamar Kunyevski

Hasalia Avner

Yoav Racchav

The present invention provides a pH dependent vaginal composition delivering a therapeutically effective amount of at least one active essentially at a pH above 4.5. The composition provides a diagnostic visual pH indication of the presence of vulvovaginitis at pH above 4.5. In the absence of such indication, the treatment may be discontinued. Another visual signal is the retrieval of the unchanged composition, which also points to a normal pH at or below 4.5 and absence of vulvovaginitis.

Methods of treatment of vaginosis and vulvovaginitis

The present application provides novel process for the preparation of glycopyrrolate tosylate.

Process for the preparation of glycopyrrolate tosylate

Provided is a process for producing highly pure 4-amino-1-isobutyl-1H-imidazo[4,5-c]quinoline (imiquimod), which includes reacting 4-chloro-1-isobutyl-1H-imidazo[4,5-c]quinoline with a non-gaseous amine precursor. Also provided are methods for isolating highly pure imiquimod. Further provided are intermediates useful in the production of imiquimod, methods for producing such intermediates, and methods for obtaining imiquimod from such intermediates.

Imiquimod production process

The present invention provides a process for preparing highly pure 4-amino-1-isobutyl-1H-imidazo[4,5-c]quinoline (imiquimod). The process preferably includes heating 4-chloro-1-isobutyl-1H-imidazo[4,5-c]quinoline of formula (II) with ammonia in a polar aprotic solvent at relatively moderate pressure to produce imiquimod, and optionally purifying the imiquimod. The process of the present invention can produce highly pure imiquimod in high yield.

The invention provides stable pharmaceutical preparations for topical and nasal uses, comprising Mupirocin calcium amorphous as an anti-microbial active agent therein, dissolved in a pharmaceutically acceptable solvent providing stability therefore.

Pharmaceutical compositions containing mupirocin

A process for the improved purification and separation of trans 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol hydrochloride from a reaction mixture containing the trans isomer, the cis isomer and Grignard reaction side products, comprising combining the mixture with a solution of hydrochloric acid in a low molecular weight alcohol or with gaseous hydrogen chloride in the presence of an organic solvent selected from medium molecular weight alcohols, ketones, esters and ethers or aromatic ethers, to effect the selective precipitation of trans 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol hydrochloride.

Process for the purification of

Growing community of inventors

Caesarea, Israel

Stephen Cherkez